Home Other Building Blocks 898280-07-4
898280-07-4,MFCD26793867
Catalog No.:AA00GU4O

898280-07-4 | XL228

Pack Size
Purity
Availability
Price(USD)
Quantity
  
5mg
≥98%
in stock  
$116.00   $81.00
- +
10mg
≥98%
in stock  
$205.00   $143.00
- +
25mg
≥98%
in stock  
$459.00   $321.00
- +
50mg
≥98%
in stock  
$823.00   $576.00
- +
250mg
≥98%
in stock  
$3,638.00   $2,547.00
- +
500mg
99% (HPLC)
in stock  
$5,515.00   $3,861.00
- +
1000mg
99% (HPLC)
in stock  
$8,787.00   $6,151.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA00GU4O
Chemical Name:
XL228
CAS Number:
898280-07-4
Molecular Formula:
C22H31N9O
Molecular Weight:
437.5412
MDL Number:
MFCD26793867
SMILES:
CN1CCN(CC1)c1nc(NCc2onc(c2)C(C)C)nc(c1)Nc1n[nH]c(c1)C1CC1
Properties
Computed Properties
 
Complexity:
598  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
32  
Hydrogen Bond Acceptor Count:
9  
Hydrogen Bond Donor Count:
3  
Rotatable Bond Count:
8  
XLogP3:
3  

Downstream Synthesis Route

[1]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]

[2]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]

[3]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]

[4]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]

[1]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]

[1]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]

[2]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]

109-01-3    438205-39-1    543713-30-0    898280-07-4   
CASUnavailable 

[1]Guz,NathanR.;Leuser,Helena;Goldman,Erick[OrganicProcessResearchandDevelopment,2013,vol.17,#8,p.1066-1073]

Literature

Title: Cortes J, et al. Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. Blood 2008 112:3232

Title: Douglas O, et al. Abstract C192: Characterization of the target profile of XL228, a multi‐targeted protein kinase inhibitor in phase 1 clinical development. Mol Cancer Ther 2009;8(12 Suppl):C192.

Title: Shah N, et al. Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228. Blood 2007 110:474;

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 898280-07-4
Tags:898280-07-4 Molecular Formula|898280-07-4 MDL|898280-07-4 SMILES|898280-07-4 XL228